BHRC BLOG
HRT for Women: Perimenopause, Menopause & What the Guidelines Say
Hormone Therapy for Women
The trial that scared a generation had an average participant aged 63. Here is what the guidelines actually say now — and what the FDA changed in November 2025.

1. What the WHI actually found, and what went wrong with the message
In 2002 the Women’s Health Initiative stopped its combined estrogen-plus-progestin arm early and reported that overall health risks exceeded benefits. The finding reshaped practice almost overnight, and hormone therapy use collapsed.
Two things about that trial were then generalised further than they should have been, and the trial’s own investigators have since said so in print.
- Age. The mean participant age was 63.3 years. Women with bothersome vasomotor symptoms typically present between 45 and 55. The FDA made this same point in its 2025 labelling rationale, describing an “age-related incongruity” between the study population and the treated population.
- Formulation and route. Only oral conjugated equine estrogens and oral medroxyprogesterone were tested. No transdermal estradiol, no micronised progesterone. The findings were then applied to every product in the class.
The investigators’ own summary is the sentence worth holding onto: younger menopausal women typically have low absolute risks of these conditions, and hormone-therapy-attributable risk in early menopause is generally less than one additional adverse event per 1,000 women per year.
2. What hormone therapy is actually indicated for
Four things, and the list is shorter than people assume:
- Moderate to severe vasomotor symptoms — hot flushes and night sweats. This is the primary indication and the strongest one.
- Genitourinary syndrome of menopause — vaginal dryness, discomfort, urinary symptoms. Local vaginal estrogen treats this at very low systemic exposure.
- Prevention of bone loss in appropriate candidates.
- Premature or early menopause, where treatment to the average age of menopause is standard.
It is not indicated for prevention of cardiovascular disease or dementia, and should not be started for those reasons. If sleep improves on hormone therapy, that is usually because night sweats stopped fragmenting it — a real and worthwhile benefit, but a secondary one.
3. The FDA labelling change — accurately described
This is recent enough that most articles are either out of date or overstating it. Here is what happened, with dates.
One more piece of context worth having. The announcement was made with unusually strong public framing. The Menopause Society endorsed the vaginal-estrogen portion without reservation but pointedly noted that systemic therapies carry different considerations and require individualised assessment. That more measured position is the one we work from.
4. Route and formulation genuinely matter

Venous thromboembolism. A large nested case-control study in the BMJ found oral estrogen-only at an adjusted odds ratio of 1.40, oral combined at 1.73, and transdermal at 0.93 — no detectable increase. In absolute terms that is roughly nine extra events per 10,000 woman-years with oral therapy. The authors concluded that transdermal treatment was the safest type and “appears to be underused.”
Stroke. A separate study found oral estrogen elevated risk at both low and high dose, while low-dose transdermal was not elevated — but high-dose transdermal was. So dose matters as well as route.
The honest framing: observational evidence consistently favours transdermal for clot risk, there are no randomised head-to-head trials, and societies regard it as a reasonable preference — particularly for women with clotting risk factors. “Proven safer” overstates it.
If you have a uterus, a progestogen is required alongside estrogen to protect the endometrium. That is not optional, and the choice of progestogen is one of the places where the breast cancer data differs between options — worth a specific conversation rather than a default.
5. Compounded hormones and pellets
We are going to be direct here, because this is where the aesthetics industry and the medical societies most visibly disagree.
The National Academies reviewed compounded bioidentical hormone therapy in 2020 and recommended restricting its use except in specific medical circumstances, noting that the FDA does not review or approve compounded preparations for safety, quality or effectiveness. The Menopause Society describes safety concerns including minimal regulation, overdosing and underdosing, impurities, lack of sterility and absence of a label outlining risks — and specifically names subdermal implants, pellets and troches as nonstandard or untested routes.
ACOG’s position is that compounded bioidentical therapy “should not be prescribed routinely when FDA-approved formulations exist,” and on pellets specifically — framed around testosterone — recommends other preparations, because a pellet is not designed to be removed. It dissolves over time, which means that if you develop an adverse effect, the dose cannot be withdrawn.
There is a legitimate role for compounding — an allergy to a component of an approved product, for instance, or a strength that is not commercially available. That is a specific clinical reason, documented for an individual. It is not the same as compounding by default.
6. If hormone therapy is not for you
Some women have contraindications, and some simply prefer not to. The non-hormonal options with real evidence:
- Fezolinetant (Veozah) — an NK3 receptor antagonist approved in May 2023, 45 mg daily. Label efficacy is a reduction of roughly 2.1–2.6 hot flushes per 24 hours versus placebo at week 4. Modest but real. It carries a boxed warning for hepatotoxicity added in December 2024, requiring liver tests before starting and then monthly for three months, and again at six and nine months.
- SSRIs and SNRIs, and gabapentin — established options with a genuine evidence base for vasomotor symptoms.
- Cognitive behavioural therapy — effective for the distress and sleep disruption, and it is the first-line treatment for insomnia in its own right, as we covered in the sleep piece.
7. Who should not take it, and for how long
Contraindications include unexplained vaginal bleeding, known or suspected estrogen-dependent cancer, active or prior venous thromboembolism or arterial thromboembolic disease, active liver disease, and known hypersensitivity. Personal and family history, clotting history and cardiovascular risk all belong in the conversation.
On duration: the guidance no longer imposes an arbitrary stop date. The old “lowest dose for the shortest time” instruction was among the language the FDA removed in November 2025. The current approach is periodic reassessment of whether benefit still outweighs risk for you — which is a better question than a fixed number of years.
8. How this works at BHRC
| What you book | Price |
|---|---|
| Consultation with full hormone and thyroid panel | $550 |
| Hormone therapy | from $550 |
Rejuvenation Club members save 20% on every treatment plus priority scheduling. The $550 entry point covers the consultation and a full hormone and thyroid panel together — which is the order things should happen in. Thyroid dysfunction and genuine deficiency both present as menopause-like symptoms, and telling them apart requires the panel.
1860 S Sepulveda Blvd, Los Angeles, CA 90025
(310) 861-3748 · Monday–Friday 9:00 AM – 6:00 PM, Saturday 9:00 AM – 4:00 PM
Monica Sotelo, NP · Medical direction by Dr. Stacey Naito, MD
4.8 stars across 287 verified reviews
Hormone consultations, advanced testing and provider-led protocols.
Consultations are free and carry no obligation.
Questions we get asked
Is hormone therapy safe?
For women under 60 or within 10 years of menopause, without contraindications, the Menopause Society considers the benefit-risk ratio favourable for treating bothersome hot flushes and preventing bone loss. Beyond that window it becomes less favourable — because baseline risk rises with age, not because the therapy changes. It is an individual assessment, not a yes-or-no.
Did the FDA remove the black box warning?
Partly, and it is still in progress. The FDA initiated removal on 10 November 2025 and approved the first six product labels on 12 February 2026. Endometrial cancer language stays for systemic estrogen-alone products. Many labels still carry the legacy warning, so the one you receive may not yet reflect the change.
Is the patch safer than the pill?
For clot risk, the observational evidence consistently favours transdermal — one large study found no detectable VTE increase with transdermal versus a clear increase with oral. There are no randomised head-to-head trials, so ‘proven safer’ overstates it. For women with clotting risk factors it is a reasonable preference.
What about pellets?
Professional societies advise against them. They are a nonstandard route, they are not FDA-approved, and — the practical objection — a pellet is designed to dissolve rather than be removed, so if you develop a side effect the dose cannot be withdrawn. ACOG recommends other preparations.
Should I have my hormones tested with saliva?
No. Both the Menopause Society and ACOG state that salivary and urine hormone testing is unreliable for determining dosing and is not recommended. A serum panel interpreted alongside your symptoms is the appropriate approach.
How long can I stay on it?
There is no longer an arbitrary limit — the ‘shortest duration’ instruction was among the language FDA removed in November 2025. The current approach is periodic reassessment of whether the benefit still outweighs the risk for you specifically.
Keep reading
- Menopause and perimenopause at BHRC
- Hormone replacement therapy — the complete guide
- Advanced lab testing — what a full panel covers
- BioTE at BHRC
- Testosterone therapy — candidacy and monitoring
- Sleep — what actually has evidence
- The BHRC longevity program
Book at any of our six locations
References
- The Menopause Society — The 2022 hormone therapy position statement of The North American Menopause Society. menopause.org
- Manson JE, et al. — The Women’s Health Initiative randomized trials and clinical practice: a review. JAMA 2024 — the investigators’ own reappraisal with absolute risks by age. jamanetwork.com
- Collaborative Group on Hormonal Factors in Breast Cancer — Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis. Lancet 2019;394(10204):1159–1168. doi.org
- U.S. Food and Drug Administration — FDA initiates removal of boxed warning from hormone therapy products, 10 November 2025. fda.gov
- Vinogradova Y, Coupland C, Hippisley-Cox J — Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies. BMJ 2019;364:k4810. bmj.com
- Renoux C, Dell’Aniello S, Garbe E, Suissa S — Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519. bmj.com
- National Academies of Sciences, Engineering, and Medicine — The clinical utility of compounded bioidentical hormone therapy: a review of safety, effectiveness, and use, 2020. nap.nationalacademies.org
- American College of Obstetricians and Gynecologists — Compounded bioidentical menopausal hormone therapy. Clinical Consensus No. 6. Obstet Gynecol 2023;142:1266–1273. acog.org
- U.S. Food and Drug Administration — VEOZAH (fezolinetant) prescribing information, including the hepatotoxicity boxed warning added December 2024. accessdata.fda.gov
- Writing Group for the Women’s Health Initiative Investigators — Risks and benefits of estrogen plus progestin in healthy postmenopausal women: the original 2002 WHI report. JAMA 2002;288(3):321–333. jamanetwork.com
Beverly Hills Rejuvenation Center. This content is for general education and does not create a physician-patient relationship or constitute medical advice. Hormone therapy is a prescription treatment requiring individual assessment. FDA labelling for these products changed from November 2025 and updates are still rolling out product by product, so a given product’s label may not yet reflect the change. Candidacy, dosing, results and pricing vary by person and are confirmed at a free consultation. Reviewed by the BHRC clinical team.